Cellosaurus logo
expasy logo

Cellosaurus MOLM-13-RES (CVCL_D779)

[Text version]
Cell line name MOLM-13-RES
Accession CVCL_D779
Resource Identification Initiative To cite this cell line use: MOLM-13-RES (RRID:CVCL_D779)
Comments Population: Japanese.
Selected for resistance to: ChEBI; CHEBI:90237; Tandutinib (MLN518; CT53518).
Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
Sequence variations
  • Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line).
  • Mutation; HGNC; 3765; FLT3; Unexplicit; Internal tandem duplication (FLT3-ITD); ClinVar=VCV000016270; Zygosity=Unspecified (from parent cell line).
Disease Adult acute myeloid leukemia (NCIt: C9154)
Myelodysplastic syndrome (NCIt: C3247)
Acute myeloid leukemia (ORDO: Orphanet_519)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_2119 (MOLM-13)
Children:
CVCL_D780 (MOLM-13-RES-AC)
Sex of cell Male
Age at sampling 20Y
Category Cancer cell line
Publications

PubMed=22354205; DOI=10.1038/leu.2012.52
Moore A.S., Faisal A., Gonzalez de Castro D., Bavetsias V., Sun C., Atrash B., Valenti M., De Haven Brandon A., Avery S., Mair D., Mirabella F., Swansbury J., Pearson A.D.J., Workman P., Blagg J., Raynaud F.I., Eccles S.A., Linardopoulos S.
Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.
Leukemia 26:1462-1470(2012)

Cross-references
Encyclopedic resources Wikidata; Q54906321
Polymorphism and mutation databases Cosmic; 1741689
Cosmic; 2842301
Entry history
Entry creation22-Oct-2012
Last entry update29-Jun-2023
Version number15